ClinicalTrials.gov record
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B

ClinicalTrials.gov ID: NCT00007332

Public ClinicalTrials.gov record NCT00007332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 2, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a Combined Regimen Using ALVAC vCP1452 and AIDSVAX B/B

Study identification

NCT ID
NCT00007332
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
330 participants

Conditions and interventions

Conditions

Interventions

  • ALVAC(2)120(B,MN)GNP (vCP1452) Biological
  • MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Mar 31, 2003
Last update posted
Oct 14, 2021

Ends 2003

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
12
Facility City State ZIP Site status
Alabama Vaccine CRS Birmingham Alabama 35294
San Francisco Dept. of Public Health, San Francisco Gen. Hosp. San Francisco California 94102
San Francisco Vaccine and Prevention CRS San Francisco California
Project Brave HIV Vaccine CRS Baltimore Maryland 21201
Johns Hopkins Bloomberg School of Public Health, Ctr. for Immunization Research, Project SAVE-DC Baltimore Maryland 21205
Johns Hopkins Bloomberg School of Public Health,Ctr for Immunization Research,Project SAVE-Baltimore Baltimore Maryland
Brigham and Women's Hosp. CRS Boston Massachusetts 02115
Fenway Community Health Clinical Research Site (FCHCRS) Boston Massachusetts 02215
Saint Louis Univ. School of Medicine, HVTU St Louis Missouri 63110
HIV Prevention & Treatment CRS New York New York 10032
NY Blood Ctr./Union Square CRS New York New York
Univ. of Rochester HVTN CRS Rochester New York 14642
NY Blood Ctr./Bronx CRS The Bronx New York 10456
Miriam Hospital's HVTU Providence Rhode Island 02906
Vanderbilt Vaccine CRS Nashville Tennessee 37232
Infectious Diseases Physicians, Inc. Annandale Virginia 22003
FHCRC/UW Vaccine CRS Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00007332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2021 · Synced May 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00007332 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →